Oncology & Cancer

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise—and induced great disappointment.

NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and nivolumab with radiation therapy (RT) did not improve progression-free survival (PFS) for patients with newly diagnosed MGMT-u…

A computational approach by St. Jude Children’s Research Hospital scientists promises to make designing T-cell-based immunotherapies that target two cancer-related antigens at the same time far easier and faster.

Skin cancer is typically caused by damage to the skin’s cells from ultraviolet radiation. But a recent case study has just shed light on another potential cause: human papillomavirus.

A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.

Ovarian cancer is the leading cause of death among women with gynecological cancers. The current medical playbook—surgery followed by chemotherapy—initially shows promise. Tumors shrink, sometimes disappearing entirely. But in more than 80% of patients…

In a discovery that could expand the array of current cancer immunotherapy treatments, scientists at Harvard Medical School have identified a new molecular brake that hinders the ability of T cells to attack tumors.

Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), according to a multicenter study led by the Hospital del Mar Research Institute, in collaboration with researchers from the CIB…

Among the many forms of liver cancer, hepatocellular carcinoma (HCC) is the most common and one of the leading causes of cancer-related deaths worldwide. It is a complex disease with multiple aggressive subtypes that are difficult to treat.

A cancer drug could enhance how patients respond to chemotherapy even in treatment-resistant tumors. The drug works by disarming a key defense mechanism that tumors use to protect themselves from treatment. In preclinical models, it has already shown p…